Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • WM-8014: Evidence Gaps in KAT6A Inhibition

    2026-10-14

    WM-8014 is described by APExBIO as a reversible, competitive inhibitor of the histone acetyltransferases KAT6A and KAT6B, with weaker reported activity against KAT5 and KAT7. The listed biochemical potency values are supplier-reported and, in the material provided, are not accompanied by an independent study, assay replication, or a head-to-head comparison using a common experimental framework. They therefore support biochemical activity claims, but do not by themselves establish selectivity in cells or animals.

    What the supplied evidence reports

    The product description reports cell-cycle arrest and cellular senescence in embryonic-day-14.5 mouse embryonic fibroblasts, together with increased Cdkn2a and reduced Cdc6 transcripts. It also describes reduced liver volume and hepatocyte proliferation in a zebrafish model of KRAS G12V-associated hepatocellular overproliferation, while stating that normal liver growth was spared. These observations are consistent with a possible role for KAT6-family activity in proliferation control and oncogene-induced senescence induction, but the supplied evidence does not provide effect sizes, replicate numbers, uncertainty estimates, or the full provenance of the underlying experiments.

    Importantly, these findings should not be read as proof that every phenotype is caused specifically by KAT6A inhibition. The reported biochemical profile includes activity against multiple MYST-family acetyltransferases, and cellular phenotypes such as senescence, reduced proliferation, or changes in Cdkn2a and Cdc6 can arise through interconnected pathways. A cell cycle arrest assay or transcriptomic change can document an outcome without uniquely identifying its molecular cause.

    Why comparative interpretation remains limited

    No direct comparison is supplied between WM-8014 and genetic KAT6A loss, another chemically distinct KAT6A inhibitor, or controls that separate KAT6A/B activity from KAT5- or KAT7-related effects. Nor does the supplied material show whether the reported potency ranking is preserved in intact cells, where protein binding, intracellular exposure, chromatin context, and compensatory signaling may alter apparent selectivity. Consequently, “KAT6A inhibitor” is a useful mechanistic description of the compound’s intended research use, but it should not be treated as evidence of exclusive KAT6A dependence.

    The supplied RESTRICT-seq preprint is identified as a 2025 bioRxiv manuscript concerning time-gated CRISPR screening and epigenetic dependencies in squamous-cell-carcinoma resistance. The record explicitly notes that it had not been certified by peer review. More importantly, the supplied information does not document that WM-8014 was used in that study. It therefore cannot serve as direct validation of WM-8014’s activity or as evidence that findings from a functional-genomics screen translate to pharmacological inhibition by this compound.

    Applicability boundaries

    The reported biological evidence comes from mouse fibroblasts and a zebrafish overproliferation model, not human tumors or clinical studies. Effects observed in those systems may depend on developmental state, oncogene context, tissue architecture, or species-specific regulation. The product description also notes high plasma-protein binding and limitations for mouse in vivo studies; that observation further cautions against equating biochemical potency with organism-level exposure or therapeutic feasibility. The suggested derivative WM-1119 is a separate compound and should not be treated as evidence for WM-8014.

    Editorial assessment

    Within the supplied record, WM-8014 is best characterized as a research compound used to interrogate an epigenetic drug target and KAT6-family-linked proliferation or senescence biology. The evidence is strongest for a reported biochemical interaction and for model-specific phenotypic associations. It is weaker for claims of cellular target specificity, causal pathway assignment, reproducibility across laboratories, and relevance to cancer treatment. For cancer biology research, the central evidence gap is not whether WM-8014 can produce a senescence-like or antiproliferative phenotype, but how reliably those outcomes can be attributed to KAT6A/B inhibition rather than broader MYST-family or context-dependent effects.